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ABSTRACT
Among existing fungal pathogens, Candida glabrata is outstanding in its capacity to rapidly develop resistance to currently
used antifungal agents. Resistance to the class of azoles, which are still widely used agents, varies in proportion (from 5 to
20%) depending on geographical area. Moreover, resistance to the class of echinocandins, which was introduced in the late
1990s, is rising in several institutions. The recent emergence of isolates with acquired resistance to both classes of agents is
a major concern since alternative therapeutic options are scarce. Although considered less pathogenic than C. albicans,
C. glabrata has still evolved specific virulence traits enabling its survival and propagation in colonized and infected hosts.
Development of drug resistance is usually associated with fitness costs, and this notion is documented across several
microbial species. Interestingly, azole resistance in C. glabrata has revealed the opposite. Experimental models of infection
showed enhanced virulence of azole-resistant isolates. Moreover, azole resistance could be associated with specific changes
in adherence properties to epithelial cells or innate immunity cells (macrophages), both of which contribute to virulence
changes. Here we will summarize the current knowledge on C. glabrata drug resistance and also discuss the consequences
of drug resistance acquisition on the balance between C. glabrata and its hosts.
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INTRODUCTION
Candida glabrata is amember of the commensalmicroflora of hu-
mans, along with other Candida species. Candida glabrata can be
isolated from different parts of the body of healthy individuals,
including the oropharynx, the stool, the vagina and,most impor-
tantly, the urinary tract, where C. glabrata is often themost com-
mon Candida species causing infection (Sobel et al. 2011). The
real proportion of asymptomatic colonization is not well known.
Most studies addressing colonization by Candida species have
been performed on hospitalized patients, with exogenous noso-
comial transmission probably skewing the numbers upwards
(Luque et al. 2009; Lau et al. 2015). In the general human popula-
tion, percentages of colonization are estimated to be anywhere
between 20 and 50%, sometimes even higher (Ghannoum et al.
2010).
Antifungal drug classes that are active against C. glabrata in-
clude polyenes, azoles, flucytosine and echinocandins. Azoles
(fluconazole, voriconazole, posaconazole and isavuconazole) in-
hibit ergosterol biosynthesis, while polyenes (amphotericin B,
AmB) bind to ergosterol in the plasma membrane where they
form large pores that disrupt cell membrane function. Flucyto-
sine (5-fluorocytosine, 5-FC) inhibits pyrimidinemetabolismand
DNA synthesis. Finally, the echinocandins (caspofungin, anidu-
lafungin and micafungin) inhibit the biosynthesis of β−1,3-D-
glucan, a major structural component of the fungal cell wall.
The use of antifungal agents is coupled with the inevitable
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Table 1.MIC values of C. albicans and C. glabrata.a)
Antifungal MIC breakpoint (mg/L) MIC breakpoint (mg/L) ECV (mg/L) EUCAST ECV (mg/L)
agent EUCAST CLSI CLSI
C. albicans C. glabrata C. albicans C. glabrata C. albicans C. glabrata C. albicans C. glabrata
S R S R S SDD R S SDD R
Ampho B ≤1 >1 ≤1 >1 ≤1 ≥1 NA NA NA 1 2 2 2
Anidulafungin ≤0.03 >0.03 ≤0.06 >0.06 ≤0.25 0.5 ≥1 ≤0.12 0.25 ≥0.5 0.03 0.12 0.12 0.25
Caspofungin NA NA NA NA ≤0.25 0.5 ≥1 ≤0.12 0.25 ≥0.5 NA NA 0.12 0.12
Micafungin ≤0.016 >0.016 ≤0.03 0.03 ≤0.25 0.5 ≥1 ≤0.06 0.12 ≥0.25 0.03 0.03 0.03 0.03
Fluconazole ≤2 >4 ≤0.002 >32 ≤2 4 ≥8 ≤32 >32 1 32 0.5 32
Voriconazole ≤0.125 >0.125 NA NA ≤0.12 0.25–0.5 ≥1 NA NA NA 0.12 1 0.03 0.5
a)Data obtained from selected publications (Rodriguez-Tudela et al. 2010; Orasch et al. 2014; Pfaller et al. 2014) and the EUCAST MIC Database
(http://mic.eucast.org/Eucast2/SearchController/).
emergence of drug resistance. The emergence of acquired drug
resistance is problematic since it restricts treatment options and
then patient management. In C. glabrata, azoles are intrinsically
less active than in C. albicans. For example, the epidemiologi-
cal cutoff value (ECV) for fluconazole, which indicates the MIC
value identifying the upper limit of the wild-type population, is
32 μg ml−1 in C. glabrata while it is only 0.5 μg ml−1 for C. albi-
cans (Pfaller et al. 2010). With regard to other agents, they exhibit
similar ECV values in both pathogenic fungal species (Table 1).
Clinical breakpoints established by either EUCAST or CLSI reflect
similar differences in activities of azoles in C. glabrata (Table 1).
Acquisition of resistance to antifungal agents is greatly
helped by the establishment of ECVs. In C. glabrata, the inci-
dence of azole resistance is variable but higher than for other
pathogens. Resistance to fluconazole among C. glabrata isolates
varies from 13.0% in the Asia-Pacific region to 19.5% in North
America (Pfaller and Diekema 2010). In the USA, resistance to
fluconazole in C. glabrata has increased from 9% in 1992–2001
to 14% in 2001–07 (Pfaller et al. 2012a). An increase can also be
detected in Europe, as exemplified by a comprehensive study
performed in Denmark (Arendrup et al. 2013). Resistance to
echinocandins has also risen significantly in C. glabratawith the
increased use of these agents in therapy. Susceptibility testing
on 1380 isolates of C. glabrata collected between 2008 and 2013
showed that 3.1, 3.3 and 3.6% of the isolates were resistant to
anidulafungin, caspofungin andmicafungin, respectively (Pham
et al. 2014). Intriguingly from this study was that, of the isolates
resistant to at least one echinocandin, 36% were also resistant
to fluconazole. The recent emergence of this type of multidrug
resistance is of concern, since it reduces possible therapeutic al-
ternatives (Pham et al. 2014). Resistance of C. glabrata to other
agents such as AmB and 5-FC is occurring more rarely (Krogh-
Madsen et al. 2006; Edlind and Katiyar 2010).
It is generally accepted that drug resistance can have some
fitness costs in several microorganisms (Melnyk, Wong and
Kassen 2014). The incidence of antifungal drug resistance being
much higher for C. glabrata than it is for C. albicans, it is impor-
tant to address the impact of antifungal drug resistance on C.
glabrata fitness. In this review, we will summarize the current
knowledge on this aspect.
Host–pathogen interactions, a well-kept balance
Like other Candida species, C. glabrata is an opportunistic
pathogen and can cause invasive infection in susceptible pa-
tients. As opportunistic pathogens, Candida species depend on
host susceptibility to initiate active infection. Microbial patho-
genesis is a relative attribute that results from the balance be-
tween both pathogen and host-associated factors (Casadevall
and Pirofski 2001) and, in accordance, the emergence of oppor-
tunistic candidiasis over the last half century is mostly due to
the expansion of the human population at risk (Edwards 1991).
Major contributors to this trend are the increased number of im-
munosuppressed patients, due to cancer, organ transplants and
the AIDS pandemic, as well as the use of broad-spectrum antibi-
otic therapy and the growth of the elderly population. Studies
tracking the origin of etiological agents of candidiasis generally
find them to be of endogenous origin (Eggimann and Pittet 2014),
meaning that preexisting colonization, either hospital acquired
or preceding hospitalization, is a requirement for infection.
With a given opportunity in patients, C. glabrata makes use
of several different virulence factors to establish active infec-
tion. Candida glabrata is less pathogenic than C. albicans, which
probably explains the predominance of C. albicans as the most
common etiological agent of invasive candidiasis. It is a helpful
exercise to think of C. glabrata pathogenesis as being of an in-
termediate degree between that of baker’s yeast Saccharomyces
cerevisiae, only relatively rarely isolated as an infectious agent
(Enache-Angoulvant and Hennequin 2005), and that of C. albi-
cans, themost common pathogenic Candida species. Genetically,
C. glabrata is more closely related to baker’s yeast than to other
Candida species (Dujon et al. 2004). Compared to baker’s yeast,
however, it has evolved specific adaptations to the commensal
lifestyle. These adaptations include virulence factors that, to-
gether with the ability to readily develop drug resistance, allow
it to cause infection. Recognized virulence factors of C. glabrata
are at least the decoration of the cell surface with a variety of ad-
hesins, the ability to undergo rapid adaptive transcriptional re-
programming when facing changing environmental conditions
and a robust resistance to both nutrient starvation and oxidative
stress (Roetzer, Gabaldon and Schuller 2011a). The C. glabrata
strategy for pathogenicity seems to be based on a ‘stealth-like’
approach. This is illustrated by the fact that it can persist in im-
munocompetent mice for weeks following systemic infection,
eliciting onlymild immune responses and pathology (Westwater
et al. 2007; Jacobsen et al. 2010). This is additionally corroborated
by its ability to cross epithelial cell barriers without significant
damage to host cells. Besides making use of the occasional ac-
cidental and medical-induced trauma to epithelial barriers (in
wounds and catheters), C. glabrata can cross intact cell barriers
such as confluent human enterocyte monolayers in vitro with
close to no damage induced to host cells (Perez-Torrado et al.
2012). Also, it readily disseminates in a chicken embryo infec-
tion model without causing mortality (Jacobsen et al. 2011). This
Vale-Silva and Sanglard 3
is consistent with the fact that, unlike C. albicans, C. glabrata
does not seem to rely on secreted hydrolases or filamentation
for host invasion (Kaur et al. 2005). The mechanisms underlying
this host cell-friendly transmigration across epithelial cell bar-
riers remain cryptic, however.
A central virulence attribute of C. glabrata, and one that
clearly separates it from baker’s yeast, is its avid adherence to
host tissues. The genome of C. glabrata contains an extensive
number of genes encoding predicted glycosyphosphatidylinosi-
tol (GPI)-anchored adhesin-like cell wall proteins (de Groot et al.
2013; Gabaldo´n et al. 2013). The number of adhesin genes ex-
hibits a wide intraspecies variability, with between 60 and 80
adhesins in different strains (L. Vale-Silva and D. Sanglard, un-
published). In addition, adhesins and other genes encoding cell
wall proteins often include mini- and megasatellites (Thierry
et al. 2008; Thierry, Dujon and Richard 2010), DNA tandem re-
peats whose size shows high intraspecies variability. Adhesin
gene number variations combined with size variability of intra-
genic tandem repeat regions reflects a large genetic plasticity
of this gene family (de Groot et al. 2013). Adhesins of C. glabrata
are divided in several subfamilies, amongwhich the EPA (EPithe-
lial Adhesion) subfamily is the most important for interaction
with host cells. The first member of this family, EPA1, was iden-
tified by Cormack, Ghori and Falkow (1999) as the main medi-
ator of adherence to epithelial cells, with its deletion reducing
adherence of C. glabrata to human epithelial cells by 95%. Most
C. glabrata adhesin genes are found in subtelomeric chromoso-
mal loci, where they are subject to transcriptional silencing by
chromatin-based regulationmechanisms (Domergue et al. 2005).
The subtelomeric gene silencing protein machinery depends
on nicotinamide adenine dinucleotide (NAD+) as a cofactor,
synthesized from nicotinic acid. Candida glabrata is a nicotinic
acid auxotroph, thus relying on environmental availability of
this precursor to synthesize NAD+. This way limitation of nico-
tinic acid availability in the urine releases subtelomeric adhesin
genes from transcriptional repression (Domergue et al. 2005).
This indirectly might mediate selective expression of adhesins
in the host’s urine, and thus configures a host environment sens-
ing mechanism likely underlying C. glabrata’s tropism to the
host’s urinary tract. Nicotinic acid limitation-based transcrip-
tional activation may also mediate biofilm formation in vivo,
with important clinical consequences for catheter-associated
infections. In this case, the phenotype relies on an additional
member of the EPA adhesin subfamily, EPA6 (Iraqui et al. 2005).
Together with the transcriptional control of EPA genes, the
dynamic processing of cell wall proteins also plays a role in the
interaction with the host. A family of 11 GPI-anchored cell wall
aspartyl proteases (yapsins, encoded by genes YPS1–YPS11), 8 of
which are found in a characteristic gene cluster in C. glabrata,
are required for virulence in murine models of systemic can-
didiasis (Kaur, Ma and Cormack 2007; Rai et al. 2012). Yapsins are
known to be involved in proteolytic processing of Epa1 (Kaur, Ma
and Cormack 2007) and many other GPI-anchored cell wall pro-
teins, which implicates them in several cellular processes. For
example, yapsins have been shown to participate in regulation
of pH homeostasis under acidic conditions and vacuole home-
ostasis (Bairwa and Kaur 2011; Bairwa et al. 2014). Yapsins are
also known to directly affect interactionwith cells of the host in-
nate immune defense, since they are required for survival of C.
glabrata within macrophages following phagocytosis (Kaur, Ma
and Cormack 2007).
Candida glabrata has long been known to be able to survive
phagocytosis and replicate within macrophages in vitro (Otto
and Howard 1976). In the phagolysosome, it faces environmen-
tal stresses like the drop in pH, oxidative stress and nutrient
deprivation. In order to cope with such stress, C. glabrata un-
dergoes drastic transcriptional remodeling (Kaur, Ma and Cor-
mack 2007; Seider et al. 2011), relying on chromatin organization
control mechanisms (Rai et al. 2012). The response mounted by
C. glabrata involves switching its metabolism to the utilization
of alternative carbon sources (Kaur, Ma and Cormack 2007), as
well as resorting to autophagy to recycle intracellular resources
and deal with nutrient starvation (Roetzer et al. 2010). Candida
glabratamay not need much adaptation to oxidative conditions,
since it is intrinsically tolerant of oxidative stress (Cuellar-Cruz
et al. 2008), but it does seem to induce antioxidant strategies
(Brunke et al. 2010; Roetzer et al. 2011b). In addition to these de-
fensive strategies, C. glabrata actively inhibits phagosome mat-
uration by different mechanisms, thus restricting the environ-
mental stresses (Seider et al. 2011; Rai et al. 2015).
In spite of its lower pathogenicity compared to C. albicans,
emergence of C. glabrata has been observed in recent years in
many regions of the world (Arendrup 2014). This trend is associ-
ated with the emergence of antifungal drug-resistant C. glabrata
isolates. Candida glabrata is intrinsically less susceptible to the
widely used azole antifungals and, upon exposure, it readily de-
velops full resistance. Resistance to more recently available an-
tifungal alternatives is emerging as well, with multidrug resis-
tance becoming an important problem in this pathogen (Pfaller
2012; Pfaller et al. 2012b; Arendrup and Perlin 2014). The ex-
tensive use of antifungal therapy and prophylaxis programs in
modern medicine may be establishing selective pressures for C.
glabrata against C. albicans.
Antifungal drug resistance mechanisms of C. glabrata
Resistance mechanisms to azoles occurring in C. glabrata have
been elucidated by several laboratories. The vast majority of
azole-resistant isolates upregulate ATP-binding cassette (ABC)
transporter genes, among which CgCDR1 and CgCDR2 play a
major role. This upregulation is mediated by a transcriptional
activator, CgPDR1, that belongs to the family of zinc finger tran-
scription factors with Zn(2)Cys(6) domains. Mutations in Cg-
PDR1, so-called gain-of-function (GOF) mutations, are responsi-
ble for the high expression of ABC transporters in azole-resistant
isolates. The GOF mutations are diverse and are located at dif-
ferent functional domains of the protein (Tsai et al. 2006, 2010;
Ferrari et al. 2009; Paul, Schmidt and Moye-Rowley 2011). It has
been shown that CgPDR1 interacts with the Mediator complex,
thus creating a link between the activator and the transcrip-
tional machinery in C. glabrata (Thakur et al. 2008). CgPDR1 regu-
lates other genes in C. glabrata due to the presence of a PDRE in
target genes. It was shown recently that CgPDR1 directly binds
to these targets genes via the PDRE (Paul, Bair and Moye-Rowley
2014). Thus, GOFmutations in CgPDR1 have not only an effect on
ABC transporter genes, but they also affect several other target
genes involved in other cellular processes. Upregulation of ABC
transporter genes can also occur without GOF mutations but in
mutants with mitochondrial defects. These mutants, so-called
petite-mutants exhibit respiratory defects. Even if their growth
rate is compromised in laboratory-grown conditions, these mu-
tants can still be obtained frompatient samples, thus suggesting
that their growth deficit can still be compensated by other yet-
unknown factors in the host (Ferrari et al. 2011a,b). Upregulation
of CgCDR1 and CgCDR2 also seems to be behind the notable azole
resistance of C. glabrata biofilms, at least during the intermedi-
ate phases of biofilm development (Song et al. 2009).
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Azole resistance mechanisms excluding efflux-mediated
mechanisms are very uncommon. To our knowledge, there is
a single report documenting that the azole target (ERG11) was
rendered non-functional by an ERG11mutation in a clinical iso-
late (Hull et al. 2012b). This is in sharp contrast with the high
incidence of this type of resistance mechanism in C. albicans
(Sanglard and Odds 2002), however with the difference that mu-
tations are affecting azole affinity in C. albicans.
Resistance to echinocandins in C. glabrata is explained by the
occurrence of mutations in genes encoding glucan synthases
(FKS1, FKS2). Elevated echinocandin MICs have been associated
with a number of single amino acid substitutions caused bymu-
tations in specific ‘hot spot’ regions of the well-conserved tar-
get genes FKS1 and FKS2 in C. glabrata. The positions, as well as
the specific amino acid substitutions, determine the degree of
MIC elevation in the individual isolate to specific echinocandins
(Arendrup and Perlin 2014).
Resistance to AmB has been rarely reported in C. glabrata.
AmB resistance in clinical isolates is caused by mutations in the
genes participating to sterol biosynthesis. Among these genes,
ERG6 and ERG2 were shown to harbor loss of function muta-
tions with the consequence of eliminating ergosterol from mu-
tant cells (Vandeputte et al. 2007, 2008; Hull et al. 2012a). Candida
glabrata has the surprising ability to be able to capture sterols
from the host and therefore to compensate for the loss of ergos-
terol by these mutations (Nagi et al. 2013).
Whole genome alterations in C. glabrata
and drug resistance
In contrast to C. albicans, a few studies have addressed whole
genome changes in C. glabrata following acquisition of drug
resistance. One study revealed a 4-fold increase in the copy
number of ERG11 in an azole-resistant isolate that corroborated
with a 8-fold increase in the corresponding mRNA. The authors
showed copy number increase of the chromosome containing
ERG11 (most probably in ChromosomeE as deduced fromCBS138
genome data). Interestingly, azole resistance could be reverted
in the isolate and also correlated with decreased ERG11 copy
number (Marichal et al. 1997). A number of other studies have
shown chromosomal pattern alterations associated with drug
resistance, however without precise mapping of drug resistance
genes (Chauhan, Kruppa and Calderone 2007). Recently, Ahmad
et al. (2013) investigated 192 C. glabrata isolates from patients
and demonstrated that these strains exhibited large karyotype
polymorphisms. Nine of these strains contained small chromo-
somes, which were smaller than 0.5 Mb. Apparently, C. glabrata
chromosomes are frequently reshuffled resulting in new ge-
netic configurations (Muller et al. 2009). These large-scale ge-
netic changes may be a common mechanism in C. glabrata of
adaptation to the host environment, and thus virulence, as well
as development of drug resistance (Pola´kova´ et al. 2009). Ahmad
et al. (2013) suggested that small chromosomes were containing
drug resistance genes (among which CgCDR2), thus contributing
to resistance development. An earlier report had already impli-
cated chromosome duplications in the development of drug re-
sistance, mainly through CgCDR1 (Shin et al. 2007).
Whole genome analysis of drug-resistant C. glabrata iso-
lates is still rare. In one remarkable study, Singh-Babak et al.
(2012) provided the first global analysis of mutations accom-
panying drug resistance in a human host utilizing a series of
C. glabrata isolates that evolved echinocandin resistance. The
whole genome sequencing identified a mutation in the drug
target, FKS2, but in addition eight non-synonymous mutations.
While the FKS2 mutation was responsible for echinocandin re-
sistance, it was associated with a fitness cost that was proba-
bly compensated by the other additional mutations. The study
could however not detect chromosomal changes due to the used
sequencing technology (Singh-Babak et al. 2012).
Our laboratory recently compared the genome sequences
of two sequential isolates, one of which developed azole re-
sistance within 50 days of therapy in a patient. The sequenc-
ing technology allowed the assembly of large fragments that
almost reconstituted entire chromosomes. While the results
showed no significant chromosomal rearrangements between
the two isolates, they exhibited a relatively small number of nu-
cleotide variations (18 non-synonymous SNPs difference). One
of the SNPs was located in CgPDR1 (L280F) and is known to be
associated with azole resistance. The other non-synonymous
changes could reflect compensatory mechanisms necessary for
host adaptations (L. Vale-Silva and D. Sanglard, unpublished).
Evolution of antifungal drug resistance
Resistance to specific antifungal agents is mediated by several
mechanisms and some of them have been resolved as above
mentioned by the alteration of specific genes. The occurrence of
thesemechanisms in clinical isolates and their selection by drug
exposure can have a cost (or fitness cost) for the overall cellular
metabolism. Fitness can be defined as the ability of an organism
to propagate and evolve within a given environment. Antifungal
resistance may have a negative impact on fitness and therefore
may reduce the competitiveness of strains as compared to wild-
type isolates, especially when the drug selection is removed.
The decrease in fitness of resistant strains may indeed compro-
mise their virulence. Some studies have addressed this question
by testing the virulence of azole-resistant C. albicans isolates as
compared to their azole-susceptible parents; however, no direct
relationship could be established between the development of
azole resistance and virulence. The trajectory of azole resistance
and the associated genome changes had rather an unpredictable
effect on fitness (Graybill et al. 1998).
In vitro studies have also addressed the relationship between
the development of azole resistance and changes in fitness. In-
dividual C. albicans colonies were subcultured in fluconazole-
containing medium and each developed individual trajectories
in their development of azole resistance (Cowen, Kohn and An-
derson 2001). These in vitro studies showedno direct relationship
between the cost of developing azole resistance and changes in
fitness as measured by competition assays between susceptible
and resistant isolates. Remarkably, in-depth analysis of genome
changes of azole-resistant isolates produced by Cowen, Kohn
and Anderson (2001) has revealed several alterations, among
which aneuploidies (for example, the formation of an isochro-
mosome from the chromosome 5 left arm, so-called 5iL). These
alterations were however not affecting in vitro fitness of C. albi-
cans (Selmecki et al. 2009). The notion of neutral fitness cost upon
azole exposure in vitro has been confirmed by others (Huang et al.
2011).
With regard to the cost of resistance to other antifungal
agents, few studies exist. Candin resistance in C. albicans has
been associated with reduced virulence in animal models (Kurtz
et al. 1996). Recent work has demonstrated that FKS1 mutations
in C. albicans resulted, in addition to candin resistance, to thicker
cell walls attributable to increased cell wall chitin content. Fks1
mutants were hypovirulent in fly and mouse models of candidi-
asis and exhibited reduced fitness in competitive mixed infec-
tion models, which may limit their epidemiological and clinical
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impact (Ben-Ami et al. 2011). Other studies have confirmed that
candin resistance results in decreased virulence as compared to
parent wild types. Fungal factor(s) critical for this negative in-
teraction are starting to be firmly identified (Slater et al. 2011;
Lee et al. 2012). Due to the cell wall remodeling action mediated
by candin resistance, recognition of fungal elements from the
host immune system probably favor host responses and there-
fore negatively impact fungal virulence (Lewis, Viale and Kon-
toyiannis 2012).
It is intriguing that during contact with cells of the innate
immune system, some genes involved in antifungal resistance
are upregulated. For example, ABC transporter genes such as
CDR1 from C. albicans and CgCDR2/PHD1 from C. glabrata are
upregulated during their phagocytosis by neutrophils and by
macrophages (Fradin et al. 2007; Kaur, Ma and Cormack 2007).
Likewise, CDR1 of C. albicans is upregulated in tissues (kidneys)
during infections (Walker et al. 2009). Moreover, strains of Cryp-
tococcus neoformans overexpressing the ABC transporter AFR1
that is responsible for fluconazole resistance exhibit enhanced
virulence in mice and alter macrophage function in an AFR1-
dependent manner to modify their survival in macrophages
(Sanguinetti et al. 2006; Orsi et al. 2009). Interestingly, azole re-
sistance involving AFR1 upregulation is mediated by aneuploidy
on a specific chromosome carrying ERG11 (Sionov et al. 2010).
In C. glabrata, a few studies have addressed the relation-
ship between acquisition of drug resistance and changes in vir-
ulence traits. As referred above, Pola´kova´ et al. (2009) and Ah-
mad et al. (2013) showed that C. glabrata is capable in the host to
form minichromosomes containing genes involved in drug re-
sistance, which may contribute to selective advantages in vivo.
Unfortunately, these studies did not address this hypothesis us-
ing animal models. As mentioned above, a study (Singh-Babak
et al. 2012) evaluated the acquisition of candin resistance by
whole genome sequence analysis of sequential isolates. The au-
thors showed that genomic mutations in addition to the ex-
pected FKS2mutation were probably the result of host pressure.
As suggested by the authors, these mutations may play a com-
pensatory role for the presence of the FKS2 mutation (Singh-
Babak et al. 2012). CgPDR1 GOF mutations and their impact on
fitness and virulence have been addressed in C. glabrata. It was
found that CgPDR1 GOF mutations, besides their role in the up-
regulation of ABC transporters and mediators of azole resis-
tance, could enhance virulence of C. glabrata as compared to
wild-type isogenic isolates in an intravenous infection model in
mice (Ferrari et al. 2009). Enhanced virulence was accompanied
by higher fungal loads in infected organs and treatment fail-
ure with azoles. Enhanced virulence could be associated with
gain of fitness of strains carrying CgPDR1 GOF. Therefore, the
results obtained by Ferrari et al. (2009) have so far challenged
the dogma existing between development of drug resistance
and fitness costs in vivo. These results have motivated the un-
derstanding of this phenomenon at the molecular level using
whole transcriptome analysis. Enhanced virulence could be due
to specific genes commonly regulated by all CgPDR1 GOFs. A de-
tailed analysis revealed that only two genes were commonly up-
regulated by at least 2-fold by all GOFs, i.e. CgCDR1, the well-
knownABC transporter involved in azole resistance, and theORF
CAGL0M12947g, which was named PUP1 (for PDR1 UPregulated
gene). This gene is highly similar to YIL077c, a gene encoding
a protein of unknown function thought be located in the mi-
tochondria. These two genes were inactivated in C. glabrata as
single mutants or combined mutants. Moreover, the two genes
were overexpressed inC. glabrata in aCgPDR1-independentman-
ner using a strong constitutive promoter (THD3). The results
showed that CgCDR1 and PUP1 deletion decreased virulence of
C. glabrata in a mice model of infection (Ferrari et al. 2011b).
Overexpression of these genes showed however intermediate
phenotypes, thus suggesting that other C. glabrata factors are
involved in the gain of virulence observed in drug-resistant
isolates.
A follow-up study investigated the role of CgPDR1 muta-
tions (Vale-Silva et al. 2013) in the interaction with murine
bone marrow-derived macrophages and human acute mono-
cytic leukemia cell line (THP-1)-derived macrophages, as well as
different epithelial cell lines. CgPDR1 GOF mutations led to de-
creased adherence to and uptake by macrophages. The interac-
tion with epithelial cells revealed an opposite trend, suggesting
that CgPDR1 GOF mutations may favor epithelial colonization of
the host by C. glabrata through increased adherence to epithelial
cell layers. These data reveal that CgPDR1 GOFmutations modu-
late the interaction with host cells in ways that may contribute
to increased virulence (Fig. 1), which is consistent with previ-
ously published results (Ferrari et al. 2009).
Recently, Borah et al. (2014) discovered an indirect connec-
tion between CgPDR1-mediated drug tolerance and the interac-
tion with the host. They showed that a tail subunit of the RNA
polymerase II mediator protein complex is essential for azole
drug tolerance, on one hand, and on the other hand its dele-
tion leads to hyperadherence to epithelial cells. The first obser-
vation can be explained with the disruption of the recruitment
of the transcriptional machinery by CgPdr1 and, consequently,
of efflux pump regulation. The adherence phenotype reflects
transcriptional regulation of the EPA1 and EPA7 genes through
an unknown mediator (Borah et al. 2014). An earlier report had
Figure 1. CgPdr1 hyperactivity modulates the interaction of C. glabrata with host cells. GOF mutations on CgPDR1 not only allow resistance to azole drugs, but also
enhance virulence of C. glabrata in murine models of disseminated candidiasis (partially mediated by CgCDR1 and PUP1 overexpression). This may be due at least
in part to an increased adherence to epithelial cells and a decreased adherence to and phagocytosis by macrophages, mediated by GOF CgPDR1 alleles in models of
interaction of C. glabrata with murine and human cells in vitro.
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already established a relationship between deletion of the sir-
tuin gene HST1 and increased expression of CgPDR1 and its tar-
get CgCDR1 (Orta-Zavalza et al. 2013). This work suggests a con-
nection between histone deacetylases, mediators of subtelom-
eric transcriptional silencing mechanisms, and CgPDR1, with
possible implications for both drug resistance and the interac-
tion with the host.
Mitochondrial dysfunction is one of the possible mecha-
nisms by which azole resistance can occur in C. glabrata. Cells
with mitochondrial DNA deficiency (so-called petite mutants)
upregulate ABC transporter genes and thus display increased
resistance to azoles. Interestingly, we recovered amitochondrial
clinicalmutant (MIC fluconazole> 256μgml−1) from clinical ori-
gin and its respiratory-competent parent (MIC fluconazole = 4
μg ml−1), which enabled to address whether mitochondrial dys-
functions conferred a selective advantage during host infection.
Surprisingly, even if the mitochondrial mutant was impaired in
growth in vitro as compared to wild type, it wasmore virulent (as
judged by mortality and fungal tissue burden) in systemic and
vaginal murine infectionmodels. The increased virulence of the
petite mutant correlated with a drastic gain of fitness in mice as
compared to its parental isolate (Ferrari et al. 2011a). Thus, this
case highlighted that antifungal resistance in C. glabrata could
result in a benefit for the fungal–host interaction, even if in vitro
growth is severely affected (Ferrari et al. 2011a).
CONCLUSIONS AND PERSPECTIVES
The development of drug resistance without counterbalancing
fitness costs, may be even showing a gain in fitness, represents
a growing problem with potentially alarming consequences.
Patients afflicted by systemic candidiasis are typically already
severely ill and therapy is difficult, often not successful, even
when the C. glabrata strain is not resistant to the drug. Conse-
quently, it will be important to prevent the emergence of re-
sistance in C. glabrata. Several measures can be taken target-
ing either the patient or the fungus. Therapeutic options aiming
to modulate the host immune system can be envisaged; how-
ever, they will be confronted with the fact that a majority of
infected patients have already partially compromised immune
defenses. Therapeutic options targeting the fungus to limit re-
sistance emergence can also be developed. Among them, drug
combinations could be proposed and recent experimental infec-
tionmodels have demonstrated their efficacy in C. glabrata (Silva
et al. 2013).
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